Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors
Well-differentiated papillary peritoneal mesothelial tumors were primarily incidental findings. There was no WDPMT-related mortality, so there was no distinct role for routine cytoreductive surgery or systemic therapy. Genomic profiles can help to differentiate WDPMT from DPM and PM.
Authors
- Ritika Kundra (ORCID: https://orcid.org/0000-0001-6723-2859)
- Garrett M. Nash (ORCID: https://orcid.org/0000-0001-9833-2625)
- Michael David Offin (ORCID: https://orcid.org/0000-0002-7959-3018)
- Marjorie G. Zauderer (ORCID: https://orcid.org/0000-0002-6109-5790)
- Andrea Cercek (ORCID: https://orcid.org/0000-0002-5054-8192)
- Marc Ladanyi (ORCID: https://orcid.org/0000-0001-9055-7213)
- Georgios Karagkounis (ORCID: https://orcid.org/0000-0003-0759-8108)
- Jennifer L. Sauter (ORCID: https://orcid.org/0000-0001-6987-2294)
- Nicole Aguirre
- Soo Ryum Yang
- Hui Mei Wang
- Marty P. Morris
- Mostafa Mohamed
- Yanming Zhang (ORCID: https://orcid.org/0009-0006-0610-9463)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1245/s10434-024-16004-2
- Citations
- 5
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- U.S. Department of Defense
- Mesothelioma Applied Research Foundation
- LUNGevity Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Novocure
- Atara Biotherapeutics
- National Institutes of Health
- National Cancer Institute